← 홈

프로그램 비교

타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-5 · 마지막 9월 2일

현재 선택: 1 · 임상 갱신 필요 1

프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.

API CSV25행 · 1개 프로그램

표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.

항목
AntibodyLimited DatastalePhase 2
Total Body Irradiation (TBI, Total Body Irradiation, Total Body Irradiation (TBI) (Plan 1))
Swedish Orphan Biovitrum·Fanconi Anemia
214 trials
Overview
Program
Total Body Irradiation (TBI) (Plan 1)
Overview
Company
Swedish Orphan Biovitrum
Overview
Modality
ANTIBODY
Overview
Target
Fanconi Anemia
Overview
Indication
Fanconi Anemia; Severe Aplastic Anemia
Overview
Phase
PHASE_2
Overview
Status
RECRUITING
Overview
Content status
Limited Data
Overview
Data Confidence
Data Confidence · Low
Overview
Development Signal
Development Signal · Emerging
Overview
Approval status
Investigational
MoA
Mechanism
targets within steroid hormone pathway
MoA
Biomarker
biomarkers will be essential to fully realize the neuroprotective and neuroregenerative potential of neurotro
PK/PD
Species
Rabbit
PK/PD
Animal (cat.)
Unknown
PK/PD
Experiment
PD
Toxicology
Species
Rabbit
Toxicology
Animal (cat.)
Unknown
Toxicology
Major finding
Time-dependent immune and skeletal alterations following total-body irradiation and hematopoietic stem cell transplantation in a murine arthritis model.. Hematopoietic stem cell transplantation (HSCT) after cytotoxic conditioning, such as total-body irradiation (TBI), is widely used to treat hematologic and immune disorders. However, this treatment is associated with long-term systemic effects, in…
Clinical
Safety signal
Time-dependent immune and skeletal alterations following total-body irradiation and hematopoietic stem cell transplantation in a murine arthritis model.. Hematopoietic stem cell transplantation (HSCT) after cytotoxic conditioning, such as total-body irradiation (TBI), is widely used to treat hematologic and immune disorders. However, this treatment is associated with long-term systemic effects, in…
Clinical
Selected reported efficacy
25%
Clinical
Result source
ClinicalTrials.gov NCT00119392
Clinical
Program phase
PHASE_2
Clinical
Trial activity
No active/completed counts
Clinical
Trial ref
NCT00119392